Axon Enterprise, Inc $AXON Holdings Increased by StoneX Group Inc.

StoneX Group Inc. grew its position in Axon Enterprise, Inc (NASDAQ:AXON) by 3,123.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,428 shares of the biotechnology company’s stock after acquiring an additional 27,546 shares during the period. StoneX Group Inc.’s holdings in Axon Enterprise were worth $12,011,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in AXON. Verus Capital Partners LLC raised its stake in shares of Axon Enterprise by 30.6% during the 3rd quarter. Verus Capital Partners LLC now owns 584 shares of the biotechnology company’s stock worth $247,000 after buying an additional 137 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Axon Enterprise by 17.7% in the third quarter. Parallel Advisors LLC now owns 1,383 shares of the biotechnology company’s stock valued at $584,000 after buying an additional 208 shares in the last quarter. Asset Dedication LLC boosted its stake in shares of Axon Enterprise by 22,054.0% in the third quarter. Asset Dedication LLC now owns 30,351 shares of the biotechnology company’s stock valued at $12,824,000 after buying an additional 30,214 shares in the last quarter. Ashton Thomas Private Wealth LLC boosted its stake in shares of Axon Enterprise by 5,072.7% in the third quarter. Ashton Thomas Private Wealth LLC now owns 110,127 shares of the biotechnology company’s stock valued at $46,531,000 after buying an additional 107,998 shares in the last quarter. Finally, CenterBook Partners LP grew its holdings in Axon Enterprise by 246.2% during the third quarter. CenterBook Partners LP now owns 4,629 shares of the biotechnology company’s stock worth $1,956,000 after acquiring an additional 3,292 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

AXON stock opened at $313.00 on Friday. The firm has a 50 day moving average of $441.53 and a 200-day moving average of $475.20. Axon Enterprise, Inc has a 12-month low of $307.00 and a 12-month high of $665.07. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. The company has a market cap of $25.43 billion, a price-to-earnings ratio of 100.32, a PEG ratio of 5.95 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). Axon Enterprise had a return on equity of 3.95% and a net margin of 7.56%. The firm had revenue of $908.55 million during the quarter, compared to analyst estimates of $934.33 million. During the same quarter in the prior year, the company earned $1.17 EPS. The business’s revenue was up 27.8% on a year-over-year basis. As a group, equities analysts expect that Axon Enterprise, Inc will post 2.10 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Morgan Stanley increased their price objective on Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Royal Bank Of Canada reduced their target price on Axon Enterprise from $735.00 to $615.00 and set an “outperform” rating for the company in a report on Friday. TD Cowen decreased their target price on shares of Axon Enterprise from $825.00 to $800.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Citigroup restated a “market outperform” rating on shares of Axon Enterprise in a research report on Monday, November 2nd. Finally, Raymond James Financial set a $675.00 price target on shares of Axon Enterprise in a research note on Thursday, October 15th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus target price of $631.35.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 16,775 shares of the business’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the sale, the president directly owned 296,974 shares in the company, valued at approximately $170,590,774.82. The trade was a 5.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Smith sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $508.99, for a total transaction of $5,089,900.00. Following the transaction, the chief executive officer directly owned 3,118,012 shares of the company’s stock, valued at approximately $1,587,036,927.88. This represents a 0.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,397 shares of company stock valued at $21,234,034 in the last three months. 4.20% of the stock is owned by company insiders.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Axon Enterprise Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.